290 related articles for article (PubMed ID: 2943798)
1. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody.
Schenkman S; Güther ML; Yoshida N
J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798
[TBL] [Abstract][Full Text] [Related]
2. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
Sher A; Hieny S; Joiner K
J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
[TBL] [Abstract][Full Text] [Related]
3. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B.
Joiner K; Sher A; Gaither T; Hammer C
Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6593-7. PubMed ID: 2944112
[TBL] [Abstract][Full Text] [Related]
4. Lytic rabbit IgG for tissue culture trypomastigotes of Trypanosoma cruzi alters the extent and form of complement deposition.
Rimoldi MT; Tartanian A; Joiner KA
Exp Parasitol; 1989 Feb; 68(2):160-7. PubMed ID: 2647504
[TBL] [Abstract][Full Text] [Related]
5. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
[TBL] [Abstract][Full Text] [Related]
6. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases.
Rimoldi MT; Sher A; Heiny S; Lituchy A; Hammer CH; Joiner K
Proc Natl Acad Sci U S A; 1988 Jan; 85(1):193-7. PubMed ID: 3277170
[TBL] [Abstract][Full Text] [Related]
7. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to metacyclic stage antigens of Trypanosoma cruzi.
Chao D; Dusanic DG
Am J Trop Med Hyg; 1985 Jul; 34(4):694-701. PubMed ID: 3927760
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific surface antigens of metacyclic trypomastigotes of Trypanosoma cruzi identified by monoclonal antibodies.
Teixeira MM; Yoshida N
Mol Biochem Parasitol; 1986 Mar; 18(3):271-82. PubMed ID: 3515178
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor.
Norris KA; Bradt B; Cooper NR; So M
J Immunol; 1991 Oct; 147(7):2240-7. PubMed ID: 1717552
[TBL] [Abstract][Full Text] [Related]
11. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
12. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
13. The alternative pathway of complement.
Pangburn MK; Müller-Eberhard HJ
Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
[No Abstract] [Full Text] [Related]
14. A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b.
Meri S; Pangburn MK
Eur J Immunol; 1990 Dec; 20(12):2555-61. PubMed ID: 2148521
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases.
Joiner KA; daSilva WD; Rimoldi MT; Hammer CH; Sher A; Kipnis TL
J Biol Chem; 1988 Aug; 263(23):11327-35. PubMed ID: 3042767
[TBL] [Abstract][Full Text] [Related]
16. Trypanosoma cruzi: recognition of trypomastigote surface antigens by lytic antisera from mice resistant to acute infection.
Yoshida N
Exp Parasitol; 1986 Apr; 61(2):184-91. PubMed ID: 3082663
[TBL] [Abstract][Full Text] [Related]
17. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
18. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
[TBL] [Abstract][Full Text] [Related]
19. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.
Norris KA
Infect Immun; 1998 Jun; 66(6):2460-5. PubMed ID: 9596703
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b.
Mold C; Kingzette M; Gewurz H
J Immunol; 1984 Aug; 133(2):882-5. PubMed ID: 6234363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
